Posted by Michael Wonder on 23 Jun 2022
Menarini Group and Radius Health submit new drug application to the U.S. FDA for elacestrant
22 June 2022 - Priority review requested; if accepted, anticipate an 8 month FDA review.
The Menarini Group and Radius Health announced that Menarini, with support from Radius, has submitted a new drug application to the U.S. FDA for elacestrant in patients with oestrogen receptor positive, HER2 negative advanced or metastatic breast cancer.
